Privacyvoorkeur
MEDtalks houdt u graag op de hoogte van de laatste ontwikkelingen op uw interessegebied. Kies hieronder of u op de hoogte gehouden wilt blijven van de nieuwste programma's en nascholingen binnen uw interessegebieden. Klik hier voor meer informatie.
ASH 2021: Journaal AML
36 min.
In dit journaal bespreekt prof. dr. Gerwin Huls zijn selectie van het belangrijkste ASH-nieuws op het gebied van acute myeloïde leukemie.
Directe links naar de ASH-abstracts:
IDH1-remming
- AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
- Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial
Secundaire AML
- Allogeneic Hematopoietic Cell Transplantation Can Overcome the Adverse Prognosis of Secondary-Type Mutation Positive De Novo Acute Myeloid Leukemia
- Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML
- Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML
Triplet-therapie
- A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study
- Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) – RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance
- Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
- Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Menin-remming
Laatst bewerkt: 20-12-2023
-
Sponsoren
Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door -
-
-
-
-
-
Specialisme
-
Tags